Abstract
Bortezomib's unprecedented antitumor activity in myeloma has long been attributed to NF-κB inhibition. A new study from the group that put the drug on the map directly challenges this assumption.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 931-932 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 114 |
| Issue number | 5 |
| DOIs |
|
| State | Published - 2009 |
| Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology